FY25 consensus $4.16. Narrows FY25 revenue view to $3.125B-$3.2B from $3.1B-$3.2B, consensus $3.14B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioMarin Expands Board with New Director Appointment
- PTC Therapeutics price target raised to $46 from $42 at Barclays
- BioMarin’s BMN 349: A Promising Step in Genetic Lung Condition Treatment
- 3 “Strong Buy” Value Stocks to Buy Now, 7/23/2025, According to Analysts